Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis.

Autor: Vitale E; Scientific Directorate, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Rizzo A; S.S.D. C.O.R.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco 65, 70124, Bari, Italy. rizzo.alessandro179@gmail.com., Maistrello L; IRCCS San Camillo Hospital, Venice, Italy., Guven DC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Massafra R; Scientific Directorate, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Monteiro FSM; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil.; Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, DF, Brazil., Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Nov 16; Vol. 14 (1), pp. 28309. Date of Electronic Publication: 2024 Nov 16.
DOI: 10.1038/s41598-024-71746-z
Abstrakt: Immune checkpoint inhibitors have revolutionized cancer treatment, but they are associated with a range of immune-related adverse events (irAEs), and emerging evidence suggests significant sex differences in the incidence, type, and severity of these toxicities, suggesting an influential factor and understanding sex-related differences in irAEs as crucial for optimizing patient care and improving clinical outcomes. In MOUSEION-07 study, we aimed to assess the association between sex and treatment-related adverse events in cancer patients treated with immunotherapy through a large up-to-date meta-analysis of available clinical trials. The present systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis. The protocol was registered with PROSPERO no. CRD42024549518. Sixteen studies encompassing a total of 4658 patients were included, and 2133 adverse effects were highlighted. The analysis observed a not statistically significant difference in terms of immune-related adverse events (irAEs) between males and females (Odds Ratio 1.19; CI 0.88-1.63) and revealed the presence of publication bias (β = -2.53; 95% CI = [-4.03; -1.04]; P = 0.006). Sex differences in immunotherapy-related adverse events are a significant factor in cancer treatment, necessitating a personalized approach to patient care. Further research is needed to fully understand the mechanisms driving these differences and to develop optimized strategies for monitoring and managing irAEs in both females and males.
Competing Interests: Competing interests The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje